

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION
(PTO-1449)

ATTY. DOCKET NO.
114232.107

SERIAL NO.
09/518,098

APPLICANT
Leland SHAPIRO

FILING DATE
May 3, 2000

GROUP

1653

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,175,253	12/29/92	Fallon et al.			
	AB	5,214,191	5/25/93	Kirschenheuter et al			
	AC	5,240,956	8/31/93	Kirschenheuter et al			
	AD	5,281,617	1/25/94	Kirschenheuter et al			
	AE	5,314,910	5/24/94	Kirschenheuter et al			
	AF	5,416,191	5/16/95	Cheronis et al			
	AG	5,478,727	12/26/95	Roizman et al			
	AH	5,486,470	1/23/96	Darke et al			
	AI	5,514,653	5/7/96	Perlmutter			
	AJ	5,610,140	3/11/97	Goodfellow et al			
	AK	5,635,593	6/3/97	Cheronis et al			
	AL	5,663,416	9/2/97	Kirschenheuter et al			
	AM	5,700,779	12/23/97	Goodfellow et al			
	AN	5,710,026	1/20/98	Sprecher			
	AO	5,712,117	1/27/98	Sprecher			
	AP	5,747,645	6/6/98	Sprecher			
	AQ	5,750,506	5/12/98	Goodfellow et al			
	AR	5,759,548	6/2/98	Bathurst et al.			
	AS	5,798,442	8/25/98	Gallant et al.			
	AT	5,811,241	9/22/98	Goodfellow et al			
	AU	5,834,431	11/10/98	Stewart et al			
	AV	5,843,900	12/1/98	Cheronis et al			
	AW	5,849,863	12/15/98	Stewart et al			
	AX	5,863,899	1/26/99	Cheronis et al			
	AY	5,874,424	2/23/99	Batchelor et al.			

EXAMINER

No reference


DATE CONSIDERED

1



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Leland SHAPIRO
SHEET 2 OF 6



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
		APPLICANT Leland SHAPIRO	
		FILING DATE May 3, 2000	GROUP 1653
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
DA	CA	Adelman S.F. et al., "Protease inhibitors suppress fibrinolytic activity of herpesvirus-transformed cells", <i>J Gen Virol</i> , 1982, 60(Pt 1):15-24.	
DA	CB	Altieri, D.C. <i>J Leukoc Biol</i> 1995, 58, 120 120 - 127	
X	CC	<i>Animal Cell Culture</i> , R. I. Freshney, ed., 1986	
DA	CD	Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. <i>Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo</i> . <i>Antimicrob Agents Chemother</i> 1995 Apr;39(4):846-9	
	CE	Beal, M.F., "Mitochondria, Free Radicals, and Neurodegeneration", <i>Curr. Opin. Neurobiol.</i> , 1996, 6, 661-666	
	CF	Beck, K.F. et al. in <i>J Exp Biol</i> 1999, 202, 645 645 - 653	
	CG	Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. <i>J Virol</i> 1990 Feb;64(2):941-3	
DA	CH	Bratt J, Palmblad J. <i>Cytokine-induced neutrophil 5 mediated injury of human endothelial cells</i> . <i>J Immunol</i> 1997 Jul 15; 159(2):812-8	
X	CI	Bukinskaya AG, Kitsak Vla, Moisiadi SA, Arakelov SA. <i>Suppression of rotavirus SA-II reproduction by protease inhibitors in cell culture</i> . <i>Vopr Virusol</i> 1987 Jan-Feb;32(1):71-4	
DA	CJ	Chesnokova NB, Maichuk YF. <i>Antiproteases in herpetic keratitis</i> . <i>Metab Pediatr Syst Ophthalmol</i> 1986;9(1):593-6	
X DA	CK	Chesnokova NB, Kasavina BS, Maichuk luF, Kazachenko MA, Shchipanova Al. <i>Main proteolytic inhibitors in ocular herpes</i> . <i>Vopr Med Khim</i> 1981 Sep-Oct;27(5):663-5	
	CL	Cilberto et al., 1995, <i>Cell</i> , 41:531-540	
	CM	Deigner, H.P. and R. Kinscherf, "Modulating Apoptosis: Current Applications and Prospects for Future Drug Development", <i>Curr Med Chem</i> 1999, 6, 399-414	
	CN	Dery, O. and Bunnett, <i>N.W. Biochem Soc Trans</i> 1999, 27, 246-254	
	CO	Dery, O. et al. <i>Am J Physiol</i> 1998, 274, C 1429-C 1452	
DA	CP	DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizman B, Colonna RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. <i>Biol Chem</i> 1993 Jan 25;268(3):2048-51	
EXAMINER <i>David Lutsey</i>		DATE CONSIDERED 12/4/01	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098	
		APPLICANT Leland SHAPIRO		
		FILING DATE May 3, 2000	GROUP	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
	CQ	Dilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonna RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. <i>J Biol Chem</i> 1994 Apr 29;269(17):12672-6		
	CR	Ding, A. et al., in <i>J. Immunol.</i> 1990, 145, 940		
	CS	Estquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. <i>Blood</i> 1996 Jun 15;87(12):4959-66		
	CT	Flaitz CM, Hicks MJ. "Molecular piracy: the viral link to carcinogenesis." <i>Oral Oncol</i> 1998 Nov;34(6):448-53		
	CU	Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV 5 infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. <i>J Immunol</i> 1996 Oct 1;157(7):2754-2758		
	CV	Goureau, O. et al., in <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1993, 90, 4276		
	CW	Griffin, William C., "Calculation of HLB Values of Non-Ionic Sufactants", [H. L. B. - The Hydophilic-Lipophilic Balance], <i>J. Soc. Cos. Met. Chem.</i> , Vol. 5, p. 249 (1954)		
	CX	Heck, D. E. et al., in <i>J. Biol. Chem.</i> 1990, 267, 21277		
	CY	Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. <i>Antiviral Res</i> 1997 Jun;35(1):1-21		
	CZ	Jabs, Thorsten, "Reactive Oxygen Intermediates as Mediators of Programmed Cell Death in Plants and Animals", <i>Biochem Pharmacol</i> 1999 57, 231-245		
	CCA	Kaufmann, Scott H., Serge Desnoyers, Yvonne Ottaviano, Nancy E. Davidson, and Guy G. Poirier, "Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis", <i>Cancer Res</i> 1993, 53, 3976		
	CCB	Kidd, Vincent J., PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS, <i>Annu Rev Physiol</i> , 1998, 60, 533		
	CCC	Kido H, Niwa Y, Beppu Y, Towatari T. <i>Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus.</i> <i>Adv Enzyme Regul</i> 1996;36:325-47		
	CCD	Kirkeboen, K.A. and Strand, O.A. in <i>Acta Anaesthesiol Scand</i> 1999, 43, 275		
	CCE	Langer, R. <i>Nature</i> 1998, 392, 5		
	CCF	List, P.J.M., et al., <i>Arterioscler Thromb Vasc Biol</i> 1999, 19, 14		
	EXAMINER			DATE CONSIDERED 12/1/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
		APPLICANT Leland SHAPIRO	
		FILING DATE May 3, 2000	GROUP 1653
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CCG	Lomas DA, Elliott PR, Carrell RW. <i>Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.</i> Eur Respir J 1997 Mar;10(3):672-5	
	CCH	Lowenstein, C. J. and Snyder, S.H. in <i>Cell</i> 1992, 70, 705-707	
	CCI	Lowenstein C. J. et al. in <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 9730	
	CCI	McCall, T.B. et al., in <i>Biochem. Biophys. Res. Commun.</i> 1992, 186, 680	
	CCK	Meki AR, Mohey El-Dean ZM. <i>Serum interleukin-1beta, interleukin-6, nitric oxide and alpha1-antitrypsin in scorpion envenomed children.</i> Toxicology 1998 Dec;36(12):1851-9	
	CCL	Molle W. et al. in <i>J Immunol</i> 1997, 159, 3555	
	CCM	Morel, J. B. and Dangle, J.L., <i>Cell Death Differ</i> 1997, 4, 671; Beal, M. F., <i>Curr Opin Neurobiol</i> 1996, 6, 661	
	CCR	Nathan, C. in <i>FASEB J.</i> 1992, 6, 3051	
	CCO	Novradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Tony Eissa N, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. <i>Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in alpha1-Antitrypsin Deficiency.</i> Am J Respir Cell Mol Biol 1999 Mar 1;20(3):441-447	
	CCP	Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S. <i>Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta.</i> Crit Care Med 1996 Nov;24(11):1903-7	
	CCQ	Patel R.P., et al. in <i>Biochim Biophys Acta</i> 1999, 1411, 385-400	
	CCR	Patel T, Gores GJ, Kaufmann SH. <i>The role of proteases during apoptosis.</i> FASEB J 1996 Apr;10(5):587-97	
	CCS	Pellegrini A, Thomas U, Franchini M, Stockli M, Klauser S, Hunziker P, von Fellenberg R. <i>Identification of an aprotinin antiviral domain.</i> FEBS Lett 1994 May 16;344(2-3):261-5	
	CCT	Popko B. and Baerwald, K. D. in <i>Neurochem Res</i> 1999, 24, 331	
	CCU	Premack, B. A. and Schall, T. J., "Chemokine Receptors: Gateways to Inflammation and Infection", <i>Nature Medicine</i> , 2, 1174-1178 (1996)	
	CCV	Pryor WA, Dooley MM, Church DF. <i>Mechanisms of cigarette smoke toxicity: the inactivation of human alpha1-proteinase inhibitor by nitric oxide/isoprene mixtures in air.</i> Chem Biol Interact 1985 Jul;54(2):171-83	
	CCW	Punjabi, C. J. et al., in <i>J. Immunol.</i> 1992, 149, 2179	
	CCX	Rehman A, Whiteman M, Halliwell B. <i>Scavenging of hydroxyl radicals but not of peroxy nitrite by inhibitors and substrates of nitric oxide syntheses.</i> Br J Pharmacol 1997 Dec; 122(8):1702-6	
EXAMINER <i>David Lattan</i>	DATE CONSIDERED 12/04/01		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 114232.107	SERIAL NO. 09/518,098
		APPLICANT Leland SHAPIRO	
		FILING DATE May 3, 2000	GROUP 1653
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
X	CCY	<i>Remington's Pharmaceutical Sciences</i> 1990, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA.	
X	CCZ	<i>Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition</i> 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.	
DL	CBA	Schini et al. in <i>Circ Res</i> 1994, 74, 24	
DL	CBC	Sharpstone D, Rowbottom A, Nelson M, Gazzard B. <i>Faecal alpha I antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.</i> Gut 1996 Feb;38(2):206-10	
DL	CBD	Shimizu T, Pommier Y. <i>DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.</i> Exp Cell Res 1996 Aug 1;226(2):292-301	
X	CBE	Sichko ZhV, Kozlova OL. <i>Experience in treating a herpetic infection with trypsin</i> [Article in Russian]. Vrach Delo 1991 Mar;(3):86-9	
DL	CBF	Smith, M. E. in <i>Neurochem Res</i> 1999, 24, 261	
X	CBG	Szeghy G, Kenyeres B. <i>On the therapy of herpes simplex keratitis with heparin and trypsin.</i> [Article in German] Klin Monatsbl Augenheilkd 1968;153(6):827-30	
X	CBH	Van Molle W, Libert C, Fiers W, Brouckaert P. <i>Alpha I-acid glycoprotein and alpha I-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice.</i> J Immunol 1997 Oct 1;159(7):3555-64	
DL	CBI	Wood, E.R. et al. in <i>Biochem Biophys Res Commun</i> 1993, 191, 767-74	
X	CBJ	Zhirnov OP, Ovcharenko AV, Mel'nikova EE, Gaidamovich Sla, Bukrinskaia AG. <i>Antiviral activity of proteinase inhibitors in cultured cells infected with alpha-viruses.</i> Mol Gen Mikrobiol Virusol 1985 Dec;(12):30-6	
EXAMINER <i>David Litten</i>		DATE CONSIDERED 12/14/01	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.